27 Sep 2022
We are delighted to be finalists in the prestigious LaingBuisson Awards 2022 in the Healthcare Outcomes category. The awards celebrate innovation and our selection is in recognition of our collaboration with University of Oxford to provide a Compassionate Access Programme utilising MR-Linac technology, providing access to NHS patients who would otherwise have had few or no options.
The aim of the programme was to
- Provide access to MRI-guided SABR free of cost to patients with medically inoperable, locally advanced, borderline resectable, or locally recurrent pancreatic cancer, particularly where other treatments weren’t available during the COVID-19 pandemic
- Build the evidence base for using MRI-guided SABR in the treatment of pancreatic cancer and to share this knowledge and expertise with the NHS oncology community
- Support the worldwide research community to find new and better ways to treat pancreatic cancer